Exonate is an early stage biotech company spun out of the University of Nottingham, that specialises in the discovery and development of innovate therapeutics that alter mRNA splicing in areas of unmet medical need. Exonate’s lead program is in ophthalmology, focused on wet Age-Related Macular Degeneration, known as wet AMD , which is the leading cause of vision loss in people aged 60 and older.
Looking for Investment?
The fund invests right across the UK and is happy to consider investments in almost any sector. While the typical first round investment tends to be in the region of £100k - £1 million the fund actively participates in follow on rounds so the overall investment in a company can be much higher.
What type of business will the fund invest in? Syndicates should be looking for the Angel CoFund to provide…Learn More
What do we mean by Angel Syndicate? For each initial investment it makes the CoFund requires a partner syndicate…Learn More
Indicative Legal Terms
When making investments the Angel CoFund (CoFund), as a co-investment fund, will generally look to adhere to existing legal…Learn More
Proposals for Investment
Proposals to the Angel CoFund may only be made by business angel syndicates. Individual businesses seeking investment are not eligible…Learn More
In order for the CoFund to make an investment, the fund’s Investment Committee will need to approve it. The basis…Learn More
How the CoFund Works
The Angel CoFund (ACF) is a UK based venture capital fund that co-invests alongside syndicates of sector-smart Angel investors,…Learn More